Antithrombotic agents in the treatment of tumors and their metastases

Clinical manifestations of hemorrhagic and thrombotic complications are observed in 30% of patients with neoplastic processes. In laboratory studies of hemostasis, cases of abnormalities reach 80-90%. Moreover, migrating thrombophlebitis is often the first manifestation of a far advanced malignant process. Thrombophlebitis in tumors is characterized by atypical localization - on hands, neck, breast, but most often - on lower leg. Thrombosis in patients with tumors of different localizations occupies the third place according to the frequency after pathology of cardiovascular system and complications arising after surgical interventions; it occurs in 18% of lethal outcomes from tumor process. Thrombosis may precede the formation of metastases. Arterial emboli and non-bacterial thrombotic endocarditis are often found in malignant diseases.